Caris Life Sciences, Inc.
CAI
$27.24
$1.134.33%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 09/30/2024 | ||
|---|---|---|---|---|---|
| Revenue | 216.83M | 181.40M | 120.92M | 101.62M | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | 216.83M | 181.40M | 120.92M | 101.62M | |
| Cost of Revenue | 69.33M | 67.71M | 63.85M | 57.21M | |
| Gross Profit | 147.51M | 113.69M | 57.06M | 44.41M | |
| SG&A Expenses | 93.24M | 106.63M | 91.95M | 77.61M | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | 184.19M | 199.39M | 178.87M | 162.46M | |
| Operating Income | 32.64M | -17.99M | -57.95M | -60.84M | |
| Income Before Tax | 24.33M | -71.79M | -102.58M | -67.73M | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | 24.33M | -71.79M | -102.58M | -67.73M | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | 24.33M | -71.79M | -102.58M | -67.73M | |
| EBIT | 32.64M | -17.99M | -57.95M | -60.84M | |
| EBITDA | 37.51M | -11.58M | -50.91M | -50.31M | |
| EPS Basic | 0.09 | -7.97 | -3.57 | -2.59 | |
| Normalized Basic EPS | 0.05 | -0.52 | -1.80 | -1.19 | |
| EPS Diluted | 0.08 | -7.97 | -3.57 | -2.59 | |
| Normalized Diluted EPS | 0.05 | -0.52 | -1.80 | -1.19 | |
| Average Basic Shares Outstanding | 282.10M | 64.92M | 35.62M | 35.64M | |
| Average Diluted Shares Outstanding | 297.21M | 64.92M | 35.62M | 35.64M | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |